Bruker
Bruker builds new businesses through strategic minority and majority investments in young technology companies, usually combined with technology collaboration. It made a majority investment to form spatial 3D genomics start-up Acuity Spatial Genomics (2021), took a minority stake in Swiss TOF mass-spectrometry maker TOFWERK (2022) and in French drug-discovery CRO NovAliX (2024). In 2026 it made a majority investment in Dutch organ-on-a-chip company MIMETAS and a minority investment in Lausanne AI lab-automation start-up Atinary, linked to its Chemspeed division.
Profile details for verified innovation managers
This profile also covers 5 collaborations, focus areas, how they work with partners, sourced facts, news. The details are visible to signed-in members who are verified as innovation managers.